Non-alcoholic fatty liver disease

HistoIndex Presents Advancements in AI-powered Stain-free Tissue Imaging for NASH Clinical Trials at EASL Congress 2023

Retrieved on: 
Wednesday, June 21, 2023
Photon, Abstract, EASL, Non-alcoholic fatty liver disease, PM, Drug development, University, TPE, CET, NASH, Hepatocellular carcinoma, Pathology, Intelligence, Research, ELF, Congress, Fibrosis, Gold, Hepatology, Patient, Algorithm, CEST, Artificial intelligence, ALT, Diagnosis, NAFLD, Entrepreneurship, AI, Digital, Mortality, AST, SHG, University of Oxford, Medical imaging, Medical device

SINGAPORE, June 21, 2023 /PRNewswire/ -- HistoIndex today announced that the Company, alongside its collaborators, will present new data on its novel stain-free tissue imaging technology using clinically validated artificial intelligence (AI) algorithms at the EASL Congress, taking place June 21-24, 2023. The data demonstrate how HistoIndex's stain-free Second Harmonic Generation/Two-Photon Excitation (SHG/TPE) imaging and AI technologies can be used in preclinical through late-stage clinical development to quantify and analyze morphological features of liver biopsy samples across Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD). HistoIndex's patented imaging technology and methodologies will be featured in 14 accepted abstracts, including one oral presentation by Dr. Timothy J. Kendall.

Key Points: 
  • HistoIndex's patented imaging technology and methodologies will be featured in 14 accepted abstracts, including one oral presentation by Dr. Timothy J. Kendall.
  • The studies presented at the EASL Congress demonstrate the successful application of SHG/TPE imaging technology combined with AI analysis in multiple clinical trials focused on NASH and NAFLD.
  • In contrast to manual assessments of stained tissue biopsies and categorical scoring systems, HistoIndex's approach eliminates variability and enhances the accuracy of diagnosis.
  • HistoIndex is participating in the EASL Congress 2023 in Vienna and will be hosting a brunch meeting on 23rd June 2023 from 10.30 am – 12 pm CET to discuss the use of stain-free digital pathology and AI as endpoints in NASH clinical trials.

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023

Retrieved on: 
Thursday, June 15, 2023
University of Oxford, EASL, Obesity, NASH, Clinical trial, Non-alcoholic fatty liver disease, NAFLD, Human body weight, Dietary supplement, Patient

GAITHERSBURG, Md., June 15, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University, will present the results of its 24-week clinical trial of pemvidutide in the treatment of non-alcoholic fatty liver disease (NAFLD) in an oral presentation at the EASL International Liver Congress™ 2023 in Vienna, Austria. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol steatohepatitis (NASH).

Key Points: 
  • Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol steatohepatitis (NASH).
  • A copy of the presentation will be accessible on the Events section of the Altimmune website.
  • Altimmune will host a reception in Vienna for NASH KOLs and investors on Thursday, June 22 at 6:30 PM CEST.
  • Please click here if you are interested in attending the reception and to receive additional details.

SUMMIT CLINICAL RESEARCH IN COLLABORATION WITH NAIL-NIT CONSORTIUM TO PRESENT GROUNDBREAKING DATA AT THE EASL CONFERENCE FROM OVER 5,000 PATIENTS COMBINED FROM MULTIPLE CLINICAL TRIALS

Retrieved on: 
Thursday, June 15, 2023
Abstract, EASL, NASH, Liver, Diabetes, Houston Methodist Hospital, Congress, Date, Committee, AGA, Data, Patient, SAN, Fatty liver disease, Non-alcoholic fatty liver disease, European Association for the Study of the Liver, Cirrhosis, Disease, Medical device, Medicine

OS—026: Performance of the AGA clinical care pathway in identifying patients with at-risk non-alcoholic steatohepatitis: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).

Key Points: 
  • OS—026: Performance of the AGA clinical care pathway in identifying patients with at-risk non-alcoholic steatohepatitis: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).
  • Date 22 June, presenter Dr. Naim Alkhouri
    THU-413: Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).
  • THU-439: Glycated hemoglobin as an independent predictor of hepatocyte ballooning in non-alcoholic steatohepatitis: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).
  • Date 22 June, presenter Dr. Mazen Noureddin
    THU-552: Comparison of non-alcoholic steatohepatitis severity between Hispanics and non-Hispanics: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).

HistoIndex SHG/TPE imaging and AI-based technology reveals dose-dependent effectiveness of Tropifexor for NASH patients in Nature Medicine

Retrieved on: 
Thursday, June 15, 2023
Photon, EASL, TPE, CET, NASH, Hepatology, Liver disease, Non-alcoholic fatty liver disease, Second-harmonic imaging microscopy, Clinical trial, Medicine, Congress, Fibrosis, VCU, Patient, Artificial intelligence, Liver, Diagnosis, AI, SHG, Cirrhosis, Medical imaging, Nature Medicine

This is mainly because traditional liver histopathology assessment of fibrosis is qualitative, nonlinear between stages, and requires substantial changes over a relatively short time before a response can be detected.

Key Points: 
  • This is mainly because traditional liver histopathology assessment of fibrosis is qualitative, nonlinear between stages, and requires substantial changes over a relatively short time before a response can be detected.
  • These biopsies were also assessed by conventional microscopy and traditional histologic scoring systems based on the categorical fibrosis stage.
  • While the conventional methods showed that only a proportion of patients achieved fibrosis improvement, the AI-based qFibrosis® algorithm showed a dose-dependent increase in the proportion of patients who achieved fibrosis improvement.
  • Tropifexor treatment was also associated with a dose-dependent reduction in qSteatosis®, which was also confirmed by a statistically significant correlation with the quantitative MRI-based evaluation of fat reduction.

Shattering the Silence: Unveiling the Quiet Epidemic of NAFLD and NASH on International NASH Day

Retrieved on: 
Wednesday, June 7, 2023
Exercise, Liver, Fatty liver disease, Obesity, International, NASH, Diabetes, Education, Health, Liver disease, Public, Risk, Inflammation, Type, Liver cancer, HIV disease progression rates, Hepatology, Metabolic syndrome, Non-alcoholic fatty liver disease, NAFLD, Liver failure, Cirrhosis, Disease, Nursing, Dietary supplement

This special day is dedicated to raising awareness about non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH).

Key Points: 
  • This special day is dedicated to raising awareness about non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH).
  • NAFLD and NASH are emerging public health concerns which currently affect over 115 million people worldwide1.
  • In Canada alone, a recent Canadian study projected a 20% increase in the frequency of NAFLD by 20302.
  • NAFLD and NASH occur when excess fat accumulates in the liver, leading to inflammation and possible liver damage.

ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Monday, May 15, 2023
Health, Science, Radiology, Research, Health Technology, Fatty liver disease, EASL, International, De novo, Marketing, Data collection, Temperature, Sale, Congress, MRI, PIN, Non-alcoholic fatty liver disease, NDRA, NAFLD, European Association for the Study of Diabetes, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical imaging, Dietary supplement, Security (finance), Liver, Diabetes

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2023 and provided a business update.
  • The data will also be used to support commercialization of the TAEUS liver device in Europe and, after FDA clearance, in the U.S.
  • The De Novo pathway is reserved for novel technologies and should assist ENDRA in achieving the strongest market position with TAEUS-optimized claims.
  • In the first quarter, ENDRA participated in the Francophone Society of Diabetes annual meeting.

Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, May 11, 2023
Health, FDA, Diabetes, Neurology, Clinical Trials, Pharmaceutical, Cardiology, Workforce, Cognitive behavioral therapy, Medical Affairs Bureau, Additive effect, Partnership, Regulation Fair Disclosure, NASH, Peer review, Marketing, Head, Disclosure, Type 2 diabetes, PDT, Better, Element, RDN, Doctor of Philosophy, De novo, Trial of the century, CBT, Regulation, Medtronic, Patient, Data, Novo Nordisk, Non-alcoholic fatty liver disease, Fatty liver disease, Webcast, NAFLD, Research, Private placement, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, T2D, Food, Pharmaceutical industry, Request

Announced Restructuring to Extend Runway Through Multiple Milestones: In March 2023, Better Therapeutics implemented a reduction in force impacting approximately 35% of the workforce.

Key Points: 
  • Announced Restructuring to Extend Runway Through Multiple Milestones: In March 2023, Better Therapeutics implemented a reduction in force impacting approximately 35% of the workforce.
  • Further Strengthen Financial Position: Better Therapeutics expects to deliver on multiple elements of its financing strategy to further enhance its financial position, including a potential business development partnership and / or royalty monetization transaction.
  • Better Therapeutics periodically provides other information for investors on its corporate website, http://www.bettertx.com , and its investor relations website, https://investors.bettertx.com .
  • Accordingly, investors should monitor Better Therapeutics’ website, in addition to following its press releases, SEC filings, and public conference calls and webcasts.

Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, May 11, 2023
Blood pressure, University of Oxford, DNA, Obesity, Dyslipidemia, NASH, Diabetes, Week, Liver disease, Weight loss, CHB, Hepatitis B virus, RNA, EDT, Fibrosis, Waist, Patient, Investment, IMPACT, Non-alcoholic fatty liver disease, NAFLD, Research, Three Months, HBV, Human, Safety, Hepatitis, Cryptocurrency, Pharmaceutical industry, Dietary supplement, Vaccine, HBsAg, Webcast

GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2023, and provided a business update.

Key Points: 
  • Webcast to be held today, May 11, 2023, at 8:30 am EDT
    GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2023, and provided a business update.
  • The trial is expected to commence mid-2023 with top-line results expected in the first quarter of 2025.
  • Data readout is expected in the first quarter of 2024 after all subjects complete the 6-month course of treatment.
  • Financial Results for the Three Months Ended March 31, 2023
    Cash, cash equivalents and short-term investments totaled $165.8 million as of March 31, 2023.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Abstract, EASL, Therapy, NASH, NAS, ISPOR, Obeticholic acid, NDA, Research, Non-alcoholic fatty liver disease, Meta-analysis, Different, Literature review, Breakthrough therapy, Evidence, Patient, Term Asset-Backed Securities Loan Facility, Institute for Clinical and Economic Review, Fibrosis, NHANES, Prevalence, ICER, Liver, Fatty liver disease, Loan, FDA, Epidemiology, Three Months, Treatment, Cirrhosis, Pharmaceutical industry, Medical imaging, Dietary supplement, Inflammation, Madrigal, Lipid

Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial

Key Points: 
  • Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial
    CONSHOHOCKEN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports first quarter 2023 financial results.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “In the first quarter of 2023, the Madrigal team made significant progress advancing our regulatory preparations, disease education initiatives, and market access strategy.
  • Additionally, we continue to execute against our clinical development objectives, and have completed enrollment of the MAESTRO-NASH trial.
  • Interest expense for the three month period ended March 31, 2023 was $2.3 million, compared to $0.0 million in the comparable prior year period.

MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions

Retrieved on: 
Thursday, May 4, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Warner, Survivor, The Next Fifty Years, Kidney failure, Diet, Therapy, Chronic kidney disease, Genetics, Face, Triglyceride, Stroke, Cholesterol, Cancer, Lipid, Ageing, Paratriathlon, COVID, Risk, Hypertension, Metabolism, Data science, Death, Metabolic syndrome, Patient, Data, DSM-IV codes, LDL, Medicine, Non-alcoholic fatty liver disease, Type, Artificial intelligence, Entrepreneurship, Multiomics, ASCVD, NAFLD, Diabetic nephropathy, Moyamoya disease, Nerve, Liver failure, AI, CKD, T2D, Machine learning, Disease, Non-executive director, Pharmaceutical industry, Medical device, Dietary supplement

MultiOmic Health , an artificial intelligence (AI)-enabled drug discovery company, has closed a £5 million (US$6.2 million) seed funding extension round to build its precision therapeutics discovery platform for metabolic syndrome-related medical conditions.

Key Points: 
  • MultiOmic Health , an artificial intelligence (AI)-enabled drug discovery company, has closed a £5 million (US$6.2 million) seed funding extension round to build its precision therapeutics discovery platform for metabolic syndrome-related medical conditions.
  • The round was led by London-based Hoxton Ventures , with participation from Ada Ventures , MMC Ventures and Verve Ventures .
  • Since beginning operations in May 2021, MultiOmic has raised a total of US$8.6 million, including an earlier round led by San Francisco-based Fifty Years .
  • Unlike cancer however, there are no existing precision medicines to tackle the specific molecular-level drivers of each metabolic syndrome disease variant.